The short answer
Kosiborod and colleagues published semaglutide in patients with heart failure with preserved ejection fraction and obesity in the New England Journal of Medicine in September 2023, followed by a pooled analysis of the STEP-HFpEF programme in the Lancet in April 2024.
Key facts
- Kosiborod 2023
- NEJM, 21 September (PMID 37622681)
- Butler 2024
- Lancet, pooled analysis (PMID 38599221)
- Population
- Obesity-related HFpEF
- Design
- Randomised, placebo-controlled
- Contrast
- Tirzepatide HFpEF data is observational
- Under regulatory review
- Reported for this indication
Why HFpEF is a distinct target
Heart failure with preserved ejection fraction is heterogeneous, and one recognised phenotype is closely tied to obesity and metabolic disease. That association makes substantial weight reduction a mechanistic hypothesis in this population specifically, rather than an opportunistic extension of an obesity drug into cardiology.
Why randomised evidence matters more here than usual
HFpEF has resisted treatment for decades, and the field carries a long record of observational associations that randomised trials failed to confirm. In that context a randomised placebo-controlled trial is not merely preferable. It is the only design the specialty is likely to accept, given how many promising associations have not survived one.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the pooled analysis adds
Butler and colleagues pooled the STEP-HFpEF programme in the Lancet in April 2024. Pooling related randomised trials increases precision and allows subgroup questions that individual trials are underpowered for, while keeping randomisation intact, the same advantage the gallbladder meta-analysis exploits.
How this sits beside the tirzepatide work
This site separately covers tirzepatide in HFpEF, which was studied by target trial emulation on retrospective cohort data. That design removes analytical biases but cannot balance unmeasured factors. STEP-HFpEF is randomised. Both concern HFpEF and they are not the same grade of evidence, which is a distinction usually lost when results are listed together.
What a regulatory filing does and does not mean
Semaglutide has been reported as under review for this indication. A submission means a sponsor considers the evidence sufficient to ask; it is not an approval, and the assessment is what determines whether the indication is granted and on what terms.
The boundary
Semaglutide is a licensed medicine and these were registered trials conducted under clinical supervision. Nothing supplied on this site is semaglutide, is related to it, or is an alternative to any treatment for heart failure.
Frequently asked questions
Why study a weight-loss drug in heart failure?
One recognised HFpEF phenotype is closely associated with obesity and metabolic disease, which makes substantial weight reduction a mechanistic hypothesis.
How does this differ from the tirzepatide HFpEF data?
STEP-HFpEF is randomised and placebo-controlled. The tirzepatide work used target trial emulation on retrospective cohort data, a weaker design.
Is it approved for heart failure?
It has been reported as under regulatory review for the indication. A submission is a request for assessment, not an approval.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKosiborod MN et al., Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. NEJM 2023 (PMID 37622681)pubmed.ncbi.nlm.nih.gov
- PubMedButler J et al., Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis. Lancet 2024 (PMID 38599221)pubmed.ncbi.nlm.nih.gov
- PubMedLin YM et al., Effectiveness of tirzepatide in HFpEF using target trial emulation. Nat Commun 2025 (PMID 40368924)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD - and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management - which is the finding.
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70-90% discounts.
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.